Katie L. Mycock, MChem

Associate Manager, Observational Research
Adelphi Real World, United Kingdom

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-396) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET